1 January 2005 Development of an optical approach for noninvasive imaging of Alzheimer's disease pathology
Author Affiliations +
J. of Biomedical Optics, 10(1), 011007 (2005). doi:10.1117/1.1846075
Abstract
Alzheimer's disease (AD) is characterized by the presence of aggregates of the amyloid-β (Aβ) peptide in the brain. These aggregates manifest themselves as senile plaques and cerebrovascular amyloid angiopathy (CAA). While traditional histochemical approaches can easily identify these deposits in postmortem tissue, only recently have specific ligands been developed to target Aβ in living patients using positron emission tomography (PET). Successful detection of Aβ pathology in patients will enable definitive preclinical diagnosis of AD, and enable quantitative evaluation of the efficacy of anti-Aβ therapeutics developed to treat the disease. PET scanning, however, has several disadvantages including high cost, low availability, and the requirement for radioactive tracers. We describe recent progress in the development of techniques for imaging Aβ deposits noninvasively using optical approaches. Successful development of an optical detection platform would enable inexpensive, accessible, nonradioactive detection of the Aβ deposits found in AD.
Jesse Skoch, Andrew K. Dunn, Bradley T. Hyman, Brian J. Bacskai, "Development of an optical approach for noninvasive imaging of Alzheimer's disease pathology," Journal of Biomedical Optics 10(1), 011007 (1 January 2005). http://dx.doi.org/10.1117/1.1846075
JOURNAL ARTICLE
7 PAGES


SHARE
KEYWORDS
Brain

Near infrared

Neuroimaging

Luminescence

Positron emission tomography

Tissues

Pathology

Back to Top